{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T22:25:07Z","timestamp":1649197507850},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,6,7]],"date-time":"2014-06-07T00:00:00Z","timestamp":1402099200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1007\/s00108-014-3465-2","type":"journal-article","created":{"date-parts":[[2014,6,26]],"date-time":"2014-06-26T11:49:34Z","timestamp":1403783374000},"page":"769-774","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapie von Demenzerkrankungen"],"prefix":"10.1007","volume":"55","author":[{"given":"F.","family":"Jessen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,6,7]]},"reference":[{"key":"3465_CR1","doi-asserted-by":"crossref","unstructured":"Savva GM, Wharton SB, Ince PG et\u00a0al (2009) Medical research council cognitive function and ageing study. Age, neuropathology, and dementia. N\u00a0Engl J Med 360:2302\u20132309","DOI":"10.1056\/NEJMoa0806142"},{"key":"3465_CR2","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1001\/archinte.163.18.2219","volume":"163","author":"Clarfield","year":"2003","unstructured":"Clarfield AM (2003) The decreasing prevalence of reversible dementias: an updated meta-analysis. Arch Intern Med 163:2219\u20132229","journal-title":"Arch Intern Med"},{"key":"3465_CR3","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1007\/s00406-010-0156-4","volume":"260","author":"Jessen","year":"2010","unstructured":"Jessen F, Kaduszkiewicz H, Daerr M et\u00a0al (2010) Anticholinergic drug use and risk for dementia: target for dementia prevention. Eur Arch Psychiatry Clin Neurosci 260(Suppl\u00a02):S111\u2013S115","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"3465_CR4","doi-asserted-by":"crossref","unstructured":"Querfurth HW, LaFerla FM (2010) Alzheimer\u2019s disease. N\u00a0Engl J Med 362:329\u2013344","DOI":"10.1056\/NEJMra0909142"},{"key":"3465_CR5","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.bbr.2010.11.058","volume":"221","author":"Schliebs","year":"2011","unstructured":"Schliebs R, Arendt T (2011) The cholinergic system in aging and neuronal degeneration. Behav Brain Res 221:555\u2013563","journal-title":"Behav Brain Res"},{"key":"3465_CR6","unstructured":"DGPPN, DGN (2010) Diagnose- und Behandlungsleitlinie Demenz. Springer-Verlag, Berlin"},{"key":"3465_CR7","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archneurol.2011.69","volume":"68","author":"Schneider","year":"2011","unstructured":"Schneider LS, Dagerman KS, Higgins JP, McShane\u00a0R (2011) Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 68:991\u2013998","journal-title":"Arch Neurol"},{"key":"3465_CR8","doi-asserted-by":"crossref","unstructured":"Howard R, McShane R, Lindesay J et\u00a0al (2012) Donepezil and memantine for moderate-to-severe Alzheimer\u2019s disease. N\u00a0Engl J Med 366:893\u2013903","DOI":"10.1056\/NEJMoa1106668"},{"key":"3465_CR9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jama.291.3.317","volume":"291","author":"Tariot","year":"2004","unstructured":"Tariot PN, Farlow MR, Grossberg GT et\u00a0al (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291:317\u2013324","journal-title":"JAMA"},{"key":"3465_CR10","first-page":"CD003120","volume":"Rev","author":"Birks","year":"2009","unstructured":"Birks J, Grimley Evans J (2009) Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev:CD003120","journal-title":"Cochrane Database Syst"},{"key":"3465_CR11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3109\/13651501.2013.814796","volume":"17","author":"Ihl","year":"2013","unstructured":"Ihl R (2013) Effects of Ginkgo biloba extract EGb\u00a0761\u00a0\u00ae in dementia with neuropsychiatric features: review of recently completed randomised, controlled trials. Int J Psychiatry Clin Pract 17(Suppl\u00a01):8\u201314","journal-title":"Int J Psychiatry Clin Pract"},{"key":"3465_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2009.10.003","volume":"6","author":"Scheltens","year":"2010","unstructured":"Scheltens P, Kamphuis PJ, Verhey FR et\u00a0al (2010) Efficacy of a medical food in mild Alzheimer\u2019s disease: a randomized, controlled trial. Alzheimers Dement 6:1\u201310","journal-title":"Alzheimers Dement"},{"key":"3465_CR13","doi-asserted-by":"crossref","unstructured":"Scheltens P, Twisk JW, Blesa R et\u00a0al (2012) Efficacy of Souvenaid in mild Alzheimer\u2019s disease: results from a randomized, controlled trial. J\u00a0Alzheimers Dis 31:225\u2013236","DOI":"10.3233\/JAD-2012-121189"},{"key":"3465_CR14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/alzrt224","volume":"5","author":"Shah","year":"2013","unstructured":"Shah RC, Kamphuis PJ, Leurgans S et\u00a0al (2013) The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer\u2019s disease. Alzheimers Res Ther 5:59","journal-title":"Alzheimers Res Ther"},{"key":"3465_CR15","doi-asserted-by":"crossref","unstructured":"Jellinger KA, Attems J (2007) Neuropathological evaluation of mixed dementia. J\u00a0Neurol Sci 257:80\u201387","DOI":"10.1016\/j.jns.2007.01.045"},{"key":"3465_CR16","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1474-4422(07)70195-3","volume":"6","author":"Kavirajan","year":"2007","unstructured":"Kavirajan H, Schneider LS (2007) Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 6:782\u2013792","journal-title":"Lancet Neurol"},{"key":"3465_CR17","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.nbd.2012.03.029","volume":"46","author":"Pagonabarraga","year":"2012","unstructured":"Pagonabarraga J, Kulisevsky J (2012) Cognitive impairment and dementia in Parkinson\u2019s disease. Neurobiol Dis 46:590\u2013596","journal-title":"Neurobiol Dis"},{"key":"3465_CR18","first-page":"297","volume":"10","author":"Riedl","year":"2014","unstructured":"Riedl L, Mackenzie IR, F\u00f6rstl H et\u00a0al (2014) Frontotemporal lobar degeneration: current perspectives. Neuropsychiatr Dis Treat 10:297\u2013310","journal-title":"Neuropsychiatr Dis Treat"},{"key":"3465_CR19","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/JGP.0b013e31823033f3","volume":"20","author":"Herrmann","year":"2012","unstructured":"Herrmann N, Black SE, Chow T et\u00a0al (2012) Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Am J Geriatr Psychiatry 20:789\u2013797","journal-title":"Am J Geriatr Psychiatry"},{"key":"3465_CR20","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/WAD.0b013e318203f208","volume":"25","author":"Okura","year":"2011","unstructured":"Okura T, Langa KM (2011) Caregiver burden and neuropsychiatric symptoms in older adults with cognitive impairment: the Aging, Demographics, and Memory Study (ADAMS). Alzheimer Dis Assoc Disord 25:116\u2013121","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"3465_CR21","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/archpsyc.60.7.737","volume":"60","author":"Lyketsos","year":"2003","unstructured":"Lyketsos CG, DelCampo L, Steinberg M et\u00a0al (2003) Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 60:737\u2013746","journal-title":"Arch Gen Psychiatry"},{"key":"3465_CR22","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/JGP.0b013e3181cc0333","volume":"18","author":"Weintraub","year":"2010","unstructured":"Weintraub D, Rosenberg PB, Drye LT et\u00a0al (2010) DIADS-2 Research Group. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry 18:332\u2013340","journal-title":"Am J Geriatr Psychiatry"},{"key":"3465_CR23","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(11)60830-1","volume":"378","author":"Banerjee","year":"2011","unstructured":"Banerjee S, Hellier J, Dewey M et\u00a0al (2011) Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 378:403\u2013411","journal-title":"Lancet"},{"key":"3465_CR24","doi-asserted-by":"crossref","unstructured":"Hausner L, Damian M, Sartorius A, Fr\u00f6lich\u00a0L (2011) Efficacy and cognitive side effects of electroconvulsive therapy (ECT) in depressed elderly inpatients with coexisting mild cognitive impairment or dementia. J\u00a0Clin Psychiatry 72:91\u201397","DOI":"10.4088\/JCP.10m05973gry"},{"key":"3465_CR25","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","volume":"294","author":"Schneider","year":"2005","unstructured":"Schneider LS, Dagerman KS, Insel P (2005) Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294:1934\u20131943","journal-title":"JAMA"},{"key":"3465_CR26","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/gps.1792","volume":"22","author":"Katz","year":"2007","unstructured":"Katz I, Deyn PP de, Mintzer J et\u00a0al (2007) The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer\u2019s disease and mixed dementia: a meta-analysis of 4\u00a0placebo-controlled clinical trials. Int J Geriatr Psychiatry 22:475\u2013484","journal-title":"Int J Geriatr Psychiatry"},{"key":"3465_CR27","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jama.2014.93","volume":"311","author":"Porsteinsson","year":"2014","unstructured":"Porsteinsson AP, Drye LT, Pollock BG et\u00a0al (2014) Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA 311:682\u2013691","journal-title":"JAMA"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-014-3465-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-014-3465-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-014-3465-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,11]],"date-time":"2019-08-11T23:12:19Z","timestamp":1565565139000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-014-3465-2"}},"subtitle":["Behandlungsstrategien im Alter"],"short-title":[],"issued":{"date-parts":[[2014,6,7]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["3465"],"URL":"https:\/\/doi.org\/10.1007\/s00108-014-3465-2","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,7]]}}}